The biological mechanisms of secondary resistance are challenging, depending on the tumor biology (EGFR mutation, co-mutations, intrinsic mutability, microenvironment and histological transformation), drug (pharmacology, inhibition of adaptative mechanisms, mutability), generation of EGFR TKIs and the line of EGFR-TKI treatment. This evidence concerns the gene EGFR and neoplasm.